Hypercholesterolemia and COVID-19: Statins for Lowering the Risk of Venous Thromboembolism.
作者信息
Vuorio Alpo, Lassila Riitta, Kovanen Petri T
机构信息
Department of Forensic Medicine, University of Helsinki, Helsinki, Finland.
Mehiläinen Airport Health Centre, Vantaa, Finland.
出版信息
Front Cardiovasc Med. 2021 Oct 13;8:711923. doi: 10.3389/fcvm.2021.711923. eCollection 2021.
Abstract
摘要
相似文献
1
Hypercholesterolemia and COVID-19: Statins for Lowering the Risk of Venous Thromboembolism.高胆固醇血症与2019冠状病毒病：他汀类药物用于降低静脉血栓栓塞风险
Front Cardiovasc Med. 2021 Oct 13;8:711923. doi: 10.3389/fcvm.2021.711923. eCollection 2021.
2
Statins for children with familial hypercholesterolemia.用于家族性高胆固醇血症儿童的他汀类药物。
Cochrane Database Syst Rev. 2014 Jul 23(7):CD006401. doi: 10.1002/14651858.CD006401.pub3.
3
Management of Hypercholesterolemia, Appropriateness of Therapeutic Approaches and New Drugs in Patients with High Cardiovascular Risk.高胆固醇血症的管理、高心血管风险患者治疗方法的适宜性及新药
High Blood Press Cardiovasc Prev. 2016 Sep;23(3):217-30. doi: 10.1007/s40292-016-0155-2. Epub 2016 Aug 27.
4
New LDL-cholesterol lowering therapies: pharmacology, clinical trials, and relevance to acute coronary syndromes.新型 LDL 胆固醇降低治疗方法：药理学、临床试验及与急性冠脉综合征的相关性。
Clin Ther. 2013 Aug;35(8):1082-98. doi: 10.1016/j.clinthera.2013.06.019. Epub 2013 Aug 8.
5
Statins for children with familial hypercholesterolemia.用于家族性高胆固醇血症儿童的他汀类药物。
Cochrane Database Syst Rev. 2010 Jul 7(7):CD006401. doi: 10.1002/14651858.CD006401.pub2.
6
[Treatment with statins in children with familial hypercholesterolemia].[他汀类药物治疗家族性高胆固醇血症儿童]
Dev Period Med. 2016;20(4):328-334.
7
New clinical perspectives of hypolipidemic drug therapy in severe hypercholesterolemia.严重高胆固醇血症中降脂药物治疗的新临床观点。
Curr Med Chem. 2012;19(28):4861-8. doi: 10.2174/092986712803341485.
8
Is the lower risk of venous thromboembolism with statins related to low-density-lipoprotein reduction? A network meta-analysis and meta-regression of randomised controlled trials.他汀类药物降低静脉血栓栓塞风险是否与降低低密度脂蛋白有关？一项随机对照试验的网络荟萃分析和荟萃回归。
Atherosclerosis. 2018 Apr;271:223-231. doi: 10.1016/j.atherosclerosis.2018.02.035. Epub 2018 Mar 2.
9
Targeting PCSK9 as a promising new mechanism for lowering low-density lipoprotein cholesterol.以 PCSK9 为靶点，降低低密度脂蛋白胆固醇：一种有前途的新机制。
Pharmacol Ther. 2016 Aug;164:183-94. doi: 10.1016/j.pharmthera.2016.04.011. Epub 2016 Apr 29.
10
Statins and prevention of venous thromboembolism: Myth or reality?他汀类药物与静脉血栓栓塞的预防：神话还是现实？
Arch Cardiovasc Dis. 2016 Mar;109(3):216-22. doi: 10.1016/j.acvd.2015.11.007. Epub 2016 Jan 14.
引用本文的文献
1
Familial Hypercholesterolemia Patients with COVID-19-Effective Cholesterol-Lowering Therapy is Urgent both during and after Infection.家族性高胆固醇血症合并新型冠状病毒肺炎患者——感染期间及感染后均急需有效的降胆固醇治疗
Rev Cardiovasc Med. 2022 Dec 19;23(12):410. doi: 10.31083/j.rcm2312410. eCollection 2022 Dec.
2
Long-Term Cardiovascular and Cerebrovascular Challenges Posed by COVID-19 in Patients With Familial Hypercholesterolemia.新冠病毒给家族性高胆固醇血症患者带来的长期心血管和脑血管挑战
Front Pharmacol. 2022 May 11;13:890141. doi: 10.3389/fphar.2022.890141. eCollection 2022.
3
Prevention of Cardiovascular Burden in COVID-19 Patients Suffering from Familial Hypercholesterolemia: A Global Challenge.预防患有家族性高胆固醇血症的COVID-19患者的心血管负担：一项全球挑战。
Cardiol Ther. 2022 Mar;11(1):1-7. doi: 10.1007/s40119-021-00245-3. Epub 2021 Nov 17.
本文引用的文献
1
Therapeutic Anticoagulation with Heparin in Noncritically Ill Patients with Covid-19.COVID-19 非危重症患者的肝素治疗性抗凝。
N Engl J Med. 2021 Aug 26;385(9):790-802. doi: 10.1056/NEJMoa2105911. Epub 2021 Aug 4.
2
The influence of pre-admission antiplatelet and anticoagulation therapy on the illness severity in hospitalized patients with COVID-19 in Japan.日本住院 COVID-19 患者入院前抗血小板和抗凝治疗对疾病严重程度的影响。
J Infect Chemother. 2021 Oct;27(10):1498-1503. doi: 10.1016/j.jiac.2021.07.016. Epub 2021 Jul 24.
3
The Residual Risk Odyssey: From LDL to Lp(a).残余风险探索之旅：从低密度脂蛋白到脂蛋白(a)
J Am Coll Cardiol. 2021 Aug 3;78(5):434-436. doi: 10.1016/j.jacc.2021.04.103.
4
Lipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL Cholesterol.脂蛋白(a)与 LDL 胆固醇控制良好患者接受 PCSK9 抑制剂治疗的获益。
J Am Coll Cardiol. 2021 Aug 3;78(5):421-433. doi: 10.1016/j.jacc.2021.04.102.
5
Intracerebral Hemorrhage in Patients With COVID-19: An Analysis From the COVID-19 Cardiovascular Disease Registry.COVID-19 相关颅内出血：COVID-19 心血管疾病登记研究的分析。
Stroke. 2021 Jul;52(7):e321-e323. doi: 10.1161/STROKEAHA.121.034215. Epub 2021 Jun 4.
6
Hospitalized Children With Familial Hypercholesterolemia and COVID-19: A Case for Preventive Anticoagulation.患有家族性高胆固醇血症和新冠病毒病的住院儿童：预防性抗凝治疗的一个案例
Front Cardiovasc Med. 2021 Apr 20;8:657719. doi: 10.3389/fcvm.2021.657719. eCollection 2021.
7
COVID-19 and Thromboinflammation: Is There a Role for Statins?COVID-19 与血栓炎症：他汀类药物有作用吗？
Clinics (Sao Paulo). 2021 Mar 24;76:e2518. doi: 10.6061/clinics/2021/e2518. eCollection 2021.
8
Association between antecedent statin use and decreased mortality in hospitalized patients with COVID-19.COVID-19 住院患者中使用他汀类药物前史与死亡率降低的关联。
Nat Commun. 2021 Feb 26;12(1):1325. doi: 10.1038/s41467-021-21553-1.
9
Arterial and venous thromboembolism in COVID-19: a study-level meta-analysis.COVID-19 相关的动脉和静脉血栓栓塞：一项基于研究水平的荟萃分析。
Thorax. 2021 Oct;76(10):970-979. doi: 10.1136/thoraxjnl-2020-215383. Epub 2021 Feb 23.
10
Statins as Adjuvant Therapy for COVID-19 to Calm the Stormy Immunothrombosis and Beyond.他汀类药物作为COVID-19的辅助治疗手段，以平息免疫性血栓形成及其他相关问题。
Front Pharmacol. 2021 Jan 19;11:579548. doi: 10.3389/fphar.2020.579548. eCollection 2020.
Zotero 插件